IP Library Granted Patent US 8,158,760
Granted Patent B2
US 8,158,760 · App. 12/351,695 · Granted Apr 17, 2012

Glycoengineered, recombinant antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,760
App. No.
12/351,695
Granted
Apr 17, 2012
Kind
B2
Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Claims (7)

1. An antibody composition comprising antibody molecules, wherein 50% or more of the molecules comprise a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region, wherein said sugar chains comprise a reduced terminal which contains an N-acetylglucosamine; wherein said sugar chains do not contain fucose bound to the 6-position of the N-acetylglucosamine in the reducing terminal of the sugar chains; and wherein said antibody molecules bind to CD20.

2. The antibody composition according to claim 1 , wherein the antibody molecules are molecules selected from the group consisting of (a), (b) and (c):

(a) human antibodies

(b) humanized antibodies

(c) antibody fragments.

3. The antibody composition according to claim 1 , wherein the antibody molecules belong to an IgG class.

4. A composition comprising the antibody composition according to claim 1 and a carrier.

Assignments (1)
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →